[HTML][HTML] In vivo target gene activation via CRISPR/Cas9-mediated trans-epigenetic modulation
HK Liao, F Hatanaka, T Araoka, P Reddy, MZ Wu, Y Sui… - Cell, 2017 - cell.com
Current genome-editing systems generally rely on inducing DNA double-strand breaks
(DSBs). This may limit their utility in clinical therapies, as unwanted mutations caused by …
(DSBs). This may limit their utility in clinical therapies, as unwanted mutations caused by …
In Vivo Target Gene Activation via CRISPR/Cas9-Mediated Trans-epigenetic Modulation
HK Liao, F Hatanaka, T Araoka, P Reddy, MZ Wu… - Cell, 2017 - pubmed.ncbi.nlm.nih.gov
Current genome-editing systems generally rely on inducing DNA double-strand breaks
(DSBs). This may limit their utility in clinical therapies, as unwanted mutations caused by …
(DSBs). This may limit their utility in clinical therapies, as unwanted mutations caused by …
[HTML][HTML] In Vivo Target Gene Activation via CRISPR/Cas9-Mediated Trans-Epigenetic Modulation
HK Liao, F Hatanaka, T Araoka, P Reddy, MZ Wu, Y Sui… - Cell, 2017 - ncbi.nlm.nih.gov
Current genome-editing systems generally rely on the creation of DNA double-strand breaks
(DSBs). This may limit their utility in clinical therapies, as unwanted mutations caused by …
(DSBs). This may limit their utility in clinical therapies, as unwanted mutations caused by …
[引用][C] In Vivo Target Gene Activation via CRISPR/Cas9-Mediated Trans-epigenetic Modulation
HK Liao, F Hatanaka, T Araoka, P Reddy, MZ Wu, Y Sui… - Cell, 2017 - cir.nii.ac.jp
[HTML][HTML] In Vivo Target Gene Activation via CRISPR/Cas9-Mediated Trans-epigenetic Modulation
HK Liao, F Hatanaka, T Araoka, P Reddy, MZ Wu, Y Sui… - Cell, 2017 - Elsevier
Current genome-editing systems generally rely on inducing DNA double-strand breaks
(DSBs). This may limit their utility in clinical therapies, as unwanted mutations caused by …
(DSBs). This may limit their utility in clinical therapies, as unwanted mutations caused by …
In Vivo Target Gene Activation via CRISPR/Cas9-Mediated Trans-epigenetic Modulation
HK Liao, F Hatanaka, T Araoka - Cell, 2017 - dialnet.unirioja.es
Current genome-editing systems generally rely on inducing DNA double-strand breaks
(DSBs). This may limit their utility in clinical therapies, as unwanted mutations caused by …
(DSBs). This may limit their utility in clinical therapies, as unwanted mutations caused by …
In Vivo Target Gene Activation via CRISPR/Cas9-Mediated Trans-epigenetic Modulation.
HK Liao, F Hatanaka, T Araoka, P Reddy, MZ Wu, Y Sui… - Cell, 2017 - europepmc.org
Current genome-editing systems generally rely on the creation of DNA double-strand breaks
(DSBs). This may limit their utility in clinical therapies, as unwanted mutations caused by …
(DSBs). This may limit their utility in clinical therapies, as unwanted mutations caused by …
[PDF][PDF] In Vivo Target Gene Activation via CRISPR/Cas9-Mediated Trans-epigenetic Modulation
HK Liao, F Hatanaka, T Araoka, P Reddy, MZ Wu, Y Sui… - Cell, 2017 - academia.edu
Current genome-editing systems generally rely on inducing DNA double-strand breaks
(DSBs). This may limit their utility in clinical therapies, as unwanted mutations caused by …
(DSBs). This may limit their utility in clinical therapies, as unwanted mutations caused by …
In Vivo Target Gene Activation via CRISPR/Cas9-Mediated Trans-epigenetic Modulation.
HK Liao, F Hatanaka, T Araoka, P Reddy, MZ Wu, Y Sui… - Cell, 2017 - escholarship.org
Current genome-editing systems generally rely on inducing DNA double-strand breaks
(DSBs). This may limit their utility in clinical therapies, as unwanted mutations caused by …
(DSBs). This may limit their utility in clinical therapies, as unwanted mutations caused by …
[引用][C] In Vivo Target Gene Activation via CRISPR/Cas9-Mediated Trans-epigenetic Modulation
HK Liao, F Hatanaka, T Araoka, P Reddy, MZ Wu… - …, 2017 - produccioncientifica.ucm.es